Chikungunya

Valneva SE (NASDAQ: VALN) completed the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553. Valneva posted topline results from the phase 3 trial in August last year. The primary endpoint result is mainly unchanged from that data drop. ...

Valneva SE (NASDAQ: VALN) has initiated a Phase 3 trial in adolescents for its single-shot chikungunya vaccine candidate, VLA1553. The collaboration falls within the framework of the agreement signed between Coalition for Epidemic Preparedness Innovations and Valneva in July 2019,...

Moderna Inc (NASDAQ: MRNA) has quietly announced the discontinuation of an mRNA program for the chikungunya virus. The Company is scrapping Phase 2 plans for mRNA-1944, the antibody directed at the chikungunya virus.  Moderna did not provide a reason for the decision, saying...

Valneva SE (NASDAQ: VALN) has announced positive topline results from the Phase 3 trial evaluating its single-shot chikungunya vaccine candidate in around 4,100 adults. Chikungunya is a mosquito-borne viral disease. Dubbed VLA1553, the vaccine candidate met its primary endpoint...

Emergent BioSolutions Inc (NYSE: EBS) has announced two-year persistence data from its Phase 2 study evaluating its investigational chikungunya virus, virus-like particle (CHIKV VLP) vaccine candidate. The CHIKV VLP vaccine is the only single-dose VLP-based vaccine currently in...